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Background: There is a high prevalence of vitamin D deﬁciency in the critically ill patient population.
Several intensive care unit studies have demonstrated an association between vitamin D deﬁciency [25-
hydroxyvitamin D (25(OH)D) < 20 ng/mL] and increased hospital length of stay (LOS), readmission rate,
sepsis and mortality.
Material and Methods: Pilot, double blind randomized control trial conducted on mechanically venti-
lated adult ICU patients. Subjects were administered either placebo, 50,000 IU vitamin D3 or 100,000 IU
vitamin D3 daily for 5 consecutive days enterally (total vitamin D3 dose = 250,000 IU or 500,000 IU, re-
spectively). The primary outcome was plasma 25(OH)D concentration 7 days after oral administration
of study drug. Secondary outcomes were plasma levels of the antimicrobial peptide cathelicidin (LL37),
hospital LOS, SOFA score, duration of mechanical ventilation, hospital mortality, mortality at 12 weeks,
and hospital acquired infection.
Results: A total of 31 subjects were enrolled with 13 (43%) being vitamin D deﬁcient at entry (25(OH)D
levels < 20 ng/mL). The 250,000 IU and 500,000 IU vitamin D3 regimens each resulted in a signiﬁcant in-
crease in mean plasma 25(OH)D concentrations from baseline to day 7; values rose to 45.7 ± 19.6 ng/
mL and 55.2 ± 14.4 ng/mL, respectively, compared to essentially no change in the placebo group (21 ± 11.2 ng/
mL), p < 0.001. There was a signiﬁcant decrease in hospital length of stay over time in the 250,000 IU
and the 500,000 IU vitamin D3 group, compared to the placebo group (25 ± 14 and 18 ± 11 days com-
pared to 36 ± 19 days, respectively; p = 0.03). There was no statically signiﬁcant change in plasma LL-37
concentrations or other clinical outcomes by group over time.
Conclusions: In this pilot study, high-dose vitamin D3 safely increased plasma 25(OH)D concentrations
into the suﬃcient range and was associated with decreased hospital length of stay without altering other
clinical outcomes.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
There is a high prevalence of vitamin D deﬁciency in the criti-
cally ill patient population, with approximately 60% of patients found
to be vitamin D deﬁcient, (25(OH)D concentrations <20 ng/mL), and
an additional 30% of patients being vitamin D insuﬃcient,
(25(OH)D = 20–30 ng/mL) [1–10]. Several intensive care unit (ICU)
studies have demonstrated an association between vitamin D de-
ﬁciency and important clinical outcomes: increased hospital length
* Corresponding author. Tel.: +404 616 0821; fax: +404 616 8455.
E-mail address: jehan2@emory.edu (J.E. Han).
1 Contributed equally to this work.
Abbreviations: 1,25-dihydroxyvitamin D, 1,25(OH)2D3 = calcitriol; 25 (OH)D, 25-
hydroxyvitamin D; AMP, antimicrobial peptides; APACHE II, acute physiology and
chronic health evaluation II; BALF, bronchial alveolar lavage ﬂuid; HAI, hospital ac-
quired infection; IU, international units; LOS, length of stay; MAP, mean arterial
pressure; SOFA, sequential organ failure assessment
2214-6237/© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
http://dx.doi.org/10.1016/j.jcte.2016.04.004
Journal of Clinical & Translational Endocrinology 4 (2016) 59–65
Contents lists available at ScienceDirect
Journal of Clinical & Translational Endocrinology
journal homepage: www.elsevier.com/ locate / jc te
of stay (LOS), readmission rates, sepsis and mortality [3–9,11,12].
Vitamin D deﬁciency is also associated with increased risk of acute
respiratory failure in critically ill patients [13,14]. Furthermore,
Dancer et al. found that vitamin D deﬁciency is nearly universal in
the development of acute respiratory distress syndrome and mech-
anistically related to lung inﬂammation and alveolar epithelial cell
injury [15].
Vitamin D has pleiotropic effects on the host immune pathway
and may be uniquely involved with lung immune function and al-
veolar capillary barrier function. In monocytes and macrophages,
pathogens bind to cell surface toll-like receptors to CYP27b1 stim-
ulate to convert 25(OH)D, the biomarker of vitamin D status, into
the active form 1,25-dihydroxyvitamin D [1,25(OH)2D3; calcitriol].
1,25(OH)2D3 in turn upregulates mRNA expression of human cat-
ionic antimicrobial protein (hCAP-18), which is cleaved to produce
LL-37, a major anti-microbial peptide (AMP) with activity against
gram-positive/gram-negative bacteria, fungi and viruses [16–18].
Although data are inconsistent, existing evidence suggests that
supplementation with vitamin D3 may decrease susceptibility or
enhance recovery to infections such as inﬂuenza, recurrent pneu-
monia and tuberculosis [19–21].
An observational study in patients with serum 25(OH)D < 20 ng/
ml found that improved vitamin D status before hospital admission
decreased the odds of all cause-mortality [22]. A recent large ran-
domized study by Amrein et al. demonstrated decreased mortality
in a subgroup of subjects with severe vitamin D deﬁciency (<12 ng/
ml) given a one-time bolus dose of 540,000 IU of enteral
cholecalciferol [23]. Leaf et al. found that lower plasma 25(OH)D
levels on admission to the ICU correlated with lower LL-37 plasma
levels that were, in turn, associated with increased 90 day mortal-
ity and sepsis risk [24,25]. In addition, a single intravenous dose of
2 μg calcitriol in adult ICU patients with severe sepsis or shock sig-
niﬁcantly upregulated leukocyte mRNA for hCAP-18 and the anti-
inﬂammatory cytokine interleukin-10 24 hours after dosing [24,26].
Therefore AMPs may be important modiﬁers of the immune re-
sponse in critically ill patients in response to vitamin D status or
exogenous administration.
We designed this pilot study to evaluate the safety and eﬃcacy
of two doses of vitamin D3, 250,000 or 500,000 IU, given in divided
doses over 5 consecutive days to increase plasma 25(OH)D con-
centrations to the suﬃcient range (>30 ng/mL) and to increase plasma
LL-37 in adult ventilated patients requiring intensive care.
Methods
Trial design
The study was approved by the Emory University Institutional
Review Board and written informed consent was obtained from the
patient or legal surrogate prior to study enrollment. The enroll-
ment goal of this pilot study was 36 patients (12 in each group) from
two Atlanta, Georgia hospitals; Emory University Hospital (EUH) and
Emory University Midtown (EUH-M). The study was registered at
www.clinicaltrials.gov (NCT01372995) and the protocol was
amended to include bronchoscopy at both baseline and study day
7. A Data Safety Monitoring Board reviewed progress and adverse
event reports every 6 months during the duration of the trial. The
entire study duration was 84 days; however, blood samples were
only taken every 7 days while the patient was hospitalized.
Participant selection
Enrollment started in July 2011 and was completed in March
2014. Inclusion criteria were: 1) receiving care in an ICU; 2) age
greater than 18 years; 3) expected to require mechanical ventila-
tion for at least 72 hours after study entry; 4) expected to survive
and remain in the ICU for at least 96 hours after study entry; and
5) enteral access in place to enable delivery of vitamin D3 or placebo
and are deemed to be able to tolerate enteral drug administration.
Exclusion criteria were: 1) inability to obtain or declined in-
formed consent from the subject and/or legally authorized
representative; 2) current pregnancy; 3) ongoing shock, [deﬁned
as unstable blood pressure despite vasopressor support and mean
arterial pressure (MAP) < 60mm Hg on at least 3 consecutive read-
ings within a 3-hour period prior to study entry]; 4) current
hypercalcemia (albumin-corrected serum calcium > 10.8 mg/dL or
ionized calcium > 5.2 mg/dL); 5) history of therapy with high-
dose vitamin D3 (greater than or equal to 50,000 IU a week) to treat
vitamin D deﬁciency, within previous 6 months; 6) history of dis-
orders associated with hypercalcemia (history of cancer with history
of hypercalcemia within the past 1 year, hyperparathyroidism, sar-
coidosis, nephrolithiasis); 7) chronic dialysis; 8) known history of
cirrhosis; 9) known HIV; and 10) received any investigational drug
within 60 days prior to study entry. The initial protocol included
bronchoscopy on day 7 of intubation, but the protocol was amended
to include a baseline bronchoscopy and then a repeat on days 5–7
if the patient remained intubated, in order to increase our sample
size. The protocol was amended in January 2012 to permit enroll-
ment of any adult critically ill mechanically ventilated patients.
Intervention
Following informed consent, subjects’ Acute Physiology and
Chronic Health Evaluation II (APACHE II) scores were calculated [27].
Treatment assignments were stratiﬁed according to clinical center
and dichotomized APACHE II score ≤ or >15. Subjects were ran-
domly assigned in a 1:1:1 ratio to placebo or a total of 250,000 IU
vitamin D3 or 500,000 IU vitamin D3 in divided equal doses over 5
days.
Treatment groups were assigned by a blinded block random-
ization schedule overseen by biostatisticians of the Atlanta Clinical
and Translational Science Institute (ACTSI) biostatistics core. The
placebo arm received two inactivemedication tablets daily for 5 days;
treatment arm 1 received one 50,000 international units (IU) of
vitamin D3 and 1 placebo pill daily for 5 days (250,000 IU total) and
treatment arm 2 received 2 pills of 50,000 IU of vitamin D3 daily
for 5 days (500,000 IU total). The medications were dissolved in
sterile water and administered through an enteral feeding tube. Cho-
lecalciferol 50,000 IU tablets were manufactured from Tischon
(Westbury, NY) and Biotech (Fayetteville, AR) and bioavailability
testing conducted during the trial showed the capsules to be within
10% of the stated dose. EUH and EUH-M Investigational Drug Service
pharmacists maintained the code and delivered all study drugs to
the respective study subject’s primary nurses for administration per
research protocol. With the exception of the pharmacists, all study
staff were blinded to the group allocation.
Clinical and demographic characteristics
Clinical and demographic data were collected at baseline. Se-
quential organ failure assessment (SOFA) [28] scores, laboratory
values and other clinical data were collected daily while the sub-
jects were hospitalized. Hospital-acquired infections (HAI) were
measured as a composite of all infectious complications that oc-
curred during hospitalization according to the 2009 Center Disease
Control deﬁnitions [29]. Measured safety parameters included serial
serum creatinine, calcium, and phosphorous concentrations, and
adverse events.
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Biospecimen collection
Twenty milliliters of venous blood was collected at baseline and
again at 7 and 14 days. The bronchoalveolar lavage procedure was
performed by serial instillation of 30 mL aliquots of normal saline
into a pulmonary subsegment and BALF was collected by suction.
BALF was centrifuged (1000 rpm; 15 min) and supernatant frozen
at −80 °C. BALF was concentrated 5- to 10-fold for 25(OH)D
determinations. Plasma 25(OH)D was measured using a
chemiluminescent-based automated machine (IDS-iSYS;
Immunodiagnostic Systems, Scottsdale, AZ). The Emory Vitamin D
laboratory participates in the Vitamin D External Quality Assess-
ment Scheme and NIST/NIH Vitamin DMetabolites Quality Assurance
Program. The 25(OH)D assay also included internal control samples
with known 25(OH)D concentrations as an additional quality
measure. Plasma LL-37 was determined by ELISA (Hycult Biotech
Inc., Plymouth Meeting, PA) and corrected according to BALF urea
concentrations.
Sample size and statistical methods
The primary outcome was the change in plasma 25(OH)D from
baseline to 7 days. Using our preliminary data [1], 12 subjects in
each group were required to test the hypothesis that high-dose
vitamin D3 would achieve plasma 25(OH)D levels ≥ 30 ng/mL with
power of 0.94 and α of 0.05. The primary analysis was according
to intent-to-treat and global tests based on a generalized linear
models, to estimate the effect of time and treatment on the out-
comes. Multiple pairwise comparisons were used to test the
difference between groups. In addition, the proportion of patients
in each group achieving 25(OH)D levels of > 30 ng/mL was com-
pared using an uncorrected chi-squared statistic. For outcomes that
were not normally distributed, such as ICU LOS and hospital LOS,
log-transformation was performed. Correlations were calculated
using Spearman’s rho (ρ). p values < 0.05 are considered signiﬁ-
cant. Based upon our previous data on plasma LL-37 levels in adult
ICU patients, enrolling 12 subjects per group provided 99% power
to detect an increase in LL-37 to levels in normal healthy subjects
(27.2 ng/mL) [1]. Planned secondary outcomes were hospital LOS,
development and/or persistence of organ dysfunction quantiﬁed
using the SOFA score, duration of mechanical ventilation, hospital
mortality, mortality at 12 weeks, and HAI.
Results
A total of 31 subjects were enrolled before project funding was
ended. Study enrollment, randomization and follow-up are shown
in the CONSORT diagram (Fig. 1). Of 658 patients screened for
inclusions/exclusion criteria, a total of 31 subjects were eligible and
randomized, and data from 30 subjects were analyzed. Per spousal
request, one patient withdrew from the study after completion of
study medication. All subjects received all study medication except
one subject who received the ﬁrst day of study drug before a de-
cision was made for comfort care; this individual was included in
the assigned intention-to-treat group. No subjects were lost to follow-
up. Baseline demographic and clinical characteristics were
comparable across all three groups (Table 1). At baseline,
comorbidities, including history of heart failure, chronic obstruc-
tive pulmonary disease, chronic kidney disease, diabetes, asthma
and diagnosis of acute infection did not differ between groups. A
history of coronary artery disease was different between groups at
baseline; 10.0% (1/10) in the placebo group, 22.2% (2/9) in the
250,000 IU vitamin D3 group, and 45.5% (7/10) in the 500,000 IU
vitamin D3 group, (p = 0.03).
Measurements of 25(OH)D
On the day of enrollment, 43% of subjects were vitamin D de-
ﬁcient with plasma 25(OH)D levels < 20 ng/mL and 40%were vitamin
D insuﬃcient, deﬁned as plasma 25(OH)D levels 20–30 ng/mL (both
similar between groups). Baseline 25(OH)D in BALF did not differ
between treatment groups (Table 1). Plasma concentrations of
25(OH)D signiﬁcantly increased from baseline in both vitamin D3
treatment groups at study day 7 (to 45 ± 20 ng/mL in the 250,000 IU
and 55 ± 14 ng/mL in the 500,000 IU vitamin D3 treatment groups,
respectively; each p < 0.001) (Fig. 2). The mean change from base-
line to day 7 in 25(OH)D levels within groups over time was
0.4 ± 7 ng/mL in the placebo group versus 26 ± 13 ng/mL and
33 ± 16 ng/mL in the 250,000 IU and 500,000 IU vitamin D3 treat-
ment groups, respectively, (p < 0.001).
Measurements of LL-37
Plasma LL-37 levels on day 7 for placebo, 250,000 IU and
500,000 IU were 62.04 ng/mL (IQR 48.56,103.02), 63.16 ng/mL (IQR
47.26,72.14) and 112.3 ng/mL (IQR 63.88,229.22), p = 0.42, respec-
tively. There was no statistically signiﬁcant change in plasma levels
of LL-37 from baseline by group over time (days 7 and 14 after entry)
and no correlation with plasma 25(OH)D levels in plasma (Table 2).
There was no signiﬁcant correlation between plasma 25(OH)D, BALF
25(OH)D, plasma LL-37 and BALF LL-37, except for a negative cor-
relation between plasma 25(OH)D concentrations and BALF 25(OH)D
concentrations across all groups over time Spearman ρ = −0.59,
(p = 0.001) (Table 3).
Table 1
Baseline demographic characteristics
Variables Placebo Vitamin D3
250,000 IU
Vitamin D3
500,000 IU
p-value
N = 10 N = 9 N = 11
Female N (%) 4 (40.0) 4 (44.4) 3 (27.3) 0.72
Race
African American 4 (40.0) 7 (77.8) 3 (27.3) 0.09
Caucasian 5 (50.0) 2 (22.2) 8 (72.7)
American Indian/Alaskan 1 (10.0) 0 (0) 0 (0)
Age, mean (SD) 64.8 (17.5) 56.4 (15.4) 68.1 (18.6) 0.22
BMI, mean (SD) 28.2 (9.9) 33.4 (6.3) 30.2 (6.1) 0.62
APACHE II, mean (SD) 23.2 (8.8) 20.0 (10.1) 19.0 (7.5) 0.55
SOFA Day 0, mean (SD) 8.6 (4.3) 8.9 (3.6) 9.1 (3.1) 0.47
Infection on admission 6 (60.0) 4 (44.4) 3 (27.3) 0.38
Admission ICU
Surgical 3 (30.0) 5 (55.6) 8 (72.7) 0.16
Medical 7 (70.0) 4 (44.4) 3 (27.3)
Baseline 25(OH)D (ng/mL),
mean (SD)
21.5 (12.2) 23.2 (7.8) 20.0 (7.3) 0.75
Baseline 25(OH)D category
Deﬁcient (<20 ng/mL) 5 (50.0) 3 (33.3) 5 (45.5) 0.87
Insuﬃcient (20–30 ng/mL) 3 (30.0) 4 (44.4) 5 (45.5)
Suﬃcient (>30 ng/mL) 2 (20.0) 2 (22.2) 1 (9.1)
Baseline 25(OH)D BALF,
mean (SD)
14.6 (9) 13 (7) 10.4 (2) 0.63a
Baseline plasma LL-37 ng/mL,
median (25%–75%IQR)
58.4 45.5 57.9
(37.2,97.3) (41.2,76.6) (37.1,284.2) 0.42
Baseline LL-37 BALF (ng/mL)
mean (SD)
1 (1.0) 4.9 0.4 (0.4) 0.17b
Coronary artery disease 1 (10.0) 2 (22.0) 7 (64.0) 0.03*
Congestive heart failure 1 (10.0) 2 (22.0) 5 (45.5) 0.20
Diabetes 4 (40.0) 1 (11.0) 2 (18.0) 0.32
COPD 2 (20.0) 1 (11.0) 4 (36.0) 0.49
Asthma 1 (10.0) 1 (11.0) 0 (0) 0.52
25(OH)D, 25 hydroxyvitamin D; BALF, bronchial alveolar lavage ﬂuid; COPD, chronic
obstructive pulmonary disease; IQR, interquartile range.
* p < 0.05 statistically signiﬁcant.
a Placebo N = 7; 250,000 N = 5, 500,000 N = 7.
b Placebo N = 4; 250,000 N = 1, 500,000 N = 1.
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Clinical outcomes
There was a difference in hospital LOS between groups; placebo
36 ± 19 days compared to 250,000 IU group 25 ± 14 days com-
pared to 500,000 IU group 18 ± 11 days, (p = 0.03) with no statistical
differences in ICU LOS or duration of mechanical ventilation (Table 4).
Changes in daily SOFA score, frequency of hospital-acquired
infections and hospital mortality were similar between groups
(Table 4).
Safety and adverse events
Mean serum calcium, creatinine and phosphorus concentra-
tions determined during each subject’s hospitalization stay were
similar between groups at all time points. There was no signiﬁ-
cant rise in calcium, creatinine and phosphorus per patient during
the entire study period (Table A1). There was no difference in adverse
events between groups. Two subjects were re-hospitalized within
30 days of drug discontinuation and those events were deemed to
not be related to study drug.
Discussion
In critically ill patients with respiratory failure, this random-
ized, controlled, double blind, pilot study demonstrated that either
of two high-dose vitamin D3 treatment regimens, given orally in
divided doses over a 5-day period, safely increased plasma 25(OH)D
to >30 ng/mL by day 7, which was sustainable at least through day
28. These pilot data suggest that high-dose vitamin D3 supplemen-
tation favorably inﬂuenced hospital LOS, complementing the recent
ﬁndings of Quraishi et al. that serum 25(OH)D levels were in-
versely associatedwith hospital LOS in surgical ICU patients [6]. From
a safety perspective, high-dose vitamin D supplementation was well
tolerated and without signiﬁcant adverse events in these critically
ill and mechanically ventilated patients.
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Figure 1. CONSORT diagram of study subject enrollment, allocation and follow-up.
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This pilot study adds to the currently limited literature of high
dose vitamin D therapy in critically ill patients, particularly by fo-
cusing on critically ill and mechanically ventilated patients without
other major comorbidities, as an important test population within
the larger population of patients with respiratory failure. In com-
parison, the VITdAL-ICU clinical trial administered 540,000 IU of
vitamin D3 as a one-time enteral dose followed by a monthly oral
dose of 90,000 IU over 5 months to mixed medical and surgical ICU
patients [30].Clinical outcomes were unaffected except for the sub-
group of patients with the lowest 25(OH)D levels (<12 ng/mL) in
which hospital mortality was signiﬁcantly decreased [30]. Our study
differed from this previous important study in that VITdAL-ICU tar-
geted hospitalized subjects who had documented 25(OH)D levels
less than 20 ng/mL, and only 65% of the VITdAL-ICU patients were
mechanically ventilated, in contrast to our study, which focused on
mechanically ventilated patients without vitamin D status eligibil-
ity requirements. Another similar study is that of Quraishi et al. who
administered 200,000 IU or 400,000 IU of vitamin D3 in critically ill
patients with sepsis and also found no correlation between 25(OH)D
and LL-37 [31]. In addition, baseline plasma 25(OH)D were similar
in both studies, although Quraishi’s post-treatment plasma 25(OH)D
and LL-37 concentrations were lower than in the current study.
Figure 2. Plasma 25-hydroxyvitamin D concentrations by group over time. At study entry the mean plasma 25(OH)D was similar across all groups. By day 7, mean plasma
25(OH)D concentrations signiﬁcantly increased in the vitamin D treatment groups compared to placebo, with sustained effects up to day 28. There was no statistical dif-
ference in the mean plasma 25(OH)D concentration between the 250,000 IU vitamin D3 group and the 500,000 IU vitamin D3 group.
Table 2
Change of plasma LL-37 overtime by groups
Placebo
(ng/mL)
Vitamin D3
250,000 IU
(ng/mL)
Vitamin D3
500,000 IU
(ng/mL)
p
value
Total number of
observations
N = 9 N = 7 N = 9
Change of plasma LL-37
day 7 compared to
baseline, median (IQR)
−3.8
(−18.9, 26.9)
6.0
(−13.4, 39.2)
−13.5
(−48.4, 37.4)
0.42
Total number of
observations
N = 8 N = 6 N = 5
Change of plasma LL-37
day 14 compared to
baseline, median (IQR)
1.1
(−24.6, 10.8)
−12.3
(−36.1, 8.1)
−6.0
(−27.3, 2.0)
0.29
Table 3
Spearman correlation of 25-hydroxyvitamin D between plasma and bronchoalveolar
lavage ﬂuid by treatment group and all subjects
Placebo Vitamin D3
250,000 IU
Vitamin D3
500,000 IU
All
Spearman coeﬃcient −0.26 −0.87 −0.76 −0.59
p value 0.47 0.05 0.03* <0.001*
* p values of <0.05 are considered statistically signiﬁcant.
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Despite a rapidly growing body of scientiﬁc literature, themecha-
nisms underlying the potential beneﬁt of high-dose vitamin D
therapy remain uncertain. Several epidemiologic studies have shown
an association between vitamin D deﬁciency and increased risk of
respiratory infections [32,33] as well as an direct relationship
between vitamin D and decreased lung function in patients with
chronic obstructive pulmonary disease and interstitial lung disease
[34–37]. Therapeutically, administration of 25(OH)D was associ-
ated with an increase in lung function for adult patients with asthma
[38] and with improved one year survival in patients with cystic
ﬁbrosis [39]. Given that vitamin D may uniquely impact lung func-
tion, it is possible that therapeutic beneﬁts of high dose vitamin D3
may be particularly evident in critically ill patients with respira-
tory failure, but this would need to be tested in a rigorous clinical
trial.
Limitations of this randomized clinical trial were the small sample
size, imbalances in chronic conditions between treatment groups
at study entry and the relatively low rate of infection in the cohort.
In addition, out of 658 patients screened we enrolled only 31 sub-
jects and caution the generalizability of our results. Also, we did not
analyze steroid use and may be an unknown confounding variable
and limitation to this study and future studies will need to monitor
corticosteroid dosing and duration as a potential confounder. Our
study is the ﬁrst in critically ill patients to administer high-dose
vitamin D in divided doses over a period of several days instead of
a one-time dose, to ensure adequate medication effect to effective-
ly test our hypotheses, as critically ill patients often have
gastrointestinal intolerance and variable drug absorption. The ran-
domized nature of the study design, with control for disease severity
in the randomization scheme, strengthens the results, although we
interpret the clinically important improvements in hospital LOS with
caution due to the risk of type I error in a pilot study. Our results
regarding LL-37 differ from Nair et al. [40], who found an increase
in serum 25(OH)D concentrations associated with increased serum
LL-37 on days 1 and 3 in critically ill patients treated with chole-
calciferol, raising the possibility that LL-37 regulation is time
dependent within the ﬁrst few days of vitamin D therapy and was
not reﬂected in our measurements at day 7 [40].
Currently, clinical practice guidelines do not exist regarding ther-
apeutic dosing of vitamin D in critically ill patients. The growing
body of literature suggests potentially important clinical beneﬁts,
such as for hospital LOS and survival, particularly for those criti-
cally ill patients with the lowest serum 25(OH)D and with infections
or respiratory failure. High-dose vitamin D may have multifacto-
rial effects that could contribute directly or indirectly to hospital
LOS, including salutary effects, via improved 25(OH)D levels on re-
spiratory or other skeletal muscle function, by modulation of the
pro-inﬂammatory milieu, and by regulation of immune functions,
among other contributors [41]. Therefore, there may be additional
musculoskeletal effects that are unknown at this time, such as pos-
itive sub-acute effects that facilitated musculoskeletal recovery and
thus expedited hospital discharge. Additional studies are needed to
deﬁne the putative mechanisms underlying such beneﬁts, and to
clearly determine the clinical outcome beneﬁts of high-dose vitamin
D3 therapy.
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